Comparison of the Area-Under-The-Curve for Vancomycin Estimated Using Compartmental and Non-compartmental Methods in Adult Patients with Normal Renal Function.
暂无分享,去创建一个
R. Day | G. Graham | J. Carland | S. Reuter | S. Stocker | Rashmi Shingde
[1] Eric Chang,et al. Review and Validation of Bayesian Dose‐Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients , 2018, Pharmacotherapy.
[2] N. Read,et al. Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus , 2018, Antimicrobial Agents and Chemotherapy.
[3] A. Schumitzky,et al. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing , 2017, Antimicrobial Agents and Chemotherapy.
[4] M. Barras,et al. Individualised medicine: why we need Bayesian dosing , 2017, Internal medicine journal.
[5] Michael N Neely,et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. , 2014, The Lancet. Infectious diseases.
[6] S. Zhai,et al. Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis , 2013, PloS one.
[7] Y. Nishi,et al. Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[8] Yong Zhang,et al. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel , 2010, Comput. Methods Programs Biomed..
[9] E. Capparelli,et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches. , 2010, International journal of clinical pharmacology and therapeutics.
[10] Tomoyoshi Inoue,et al. Population Pharmacokinetic Analysis of Vancomycin Using Serum Cystatin C as a Marker of Renal Function , 2009, Antimicrobial Agents and Chemotherapy.
[11] C. Staatz,et al. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. , 2009, The Journal of antimicrobial chemotherapy.
[12] C. Staatz,et al. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery. , 2006, British journal of clinical pharmacology.
[13] M. J. García,et al. Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies , 2005, Antimicrobial Agents and Chemotherapy.
[14] N. Milpied,et al. Application of USC*PACK clinical programs to vancomycin in neutropenic patients. , 1994, International journal of bio-medical computing.
[15] R W Jelliffe,et al. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens , 1990, Antimicrobial Agents and Chemotherapy.
[16] W. Keane,et al. Pharmacokinetics of vancomycin in patients with various degrees of renal function , 1984, Antimicrobial Agents and Chemotherapy.
[17] R. Blouin,et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects , 1982, Antimicrobial Agents and Chemotherapy.
[18] D. DuBois,et al. FIFTH PAPER THE MEASUREMENT OF THE SURFACE AREA OF MAN , 1915 .
[19] Y. Nishi,et al. Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring , 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[20] B. Bruguerolle,et al. Vancomycin: a review of population pharmacokinetic analyses. , 2012, Clinical pharmacokinetics.
[21] Sara E Cosgrove,et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] D. Levine,et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[23] M. Rybak,et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.